Tygacil

Before taking this medicine

Do not use Tygacil if you are allergic to tigecycline or any of its ingredients. It should also be avoided if you have a known allergy to tetracyclines. Severe, potentially life-threatening allergic reactions have been reported. Clinical trials found a higher risk of death in patients treated with Tygacil than in those receiving comparison treatments. The cause is unknown. The greatest difference was seen in patients with ventilator-associated pneumonia. Liver problems and pancreatitis, including fatal cases, have been reported. Abnormal liver tests require monitoring and reassessment of whether treatment should continue. If pancreatitis is suspected, the prescriber should consider stopping treatment. Tygacil can also lower fibrinogen, a protein involved in blood clotting. Blood clotting tests, including fibrinogen, should be checked before and regularly during treatment. Diarrhea during treatment requires assessment for Clostridioides difficile-associated diarrhea. Use during the last half of pregnancy, infancy or childhood up to age 8 may permanently discolor teeth and affect tooth enamel. Use during the second or third trimester of pregnancy, infancy or childhood up to age 8 may temporarily inhibit bone growth. Use in anyone under 18 is not recommended because of the higher risk of death seen in adult trials. Avoid breastfeeding for longer than 3 weeks while receiving Tygacil. An alternative is to pump and discard breast milk during treatment and for 9 days after the last dose.